retatrutide parkinson's clinical trial First phase 3 data for are here folks. This drug is a barn burner. This was only 68 weeks and was geared towards osteoarthritis of the knee. Massive pain improvements and Retatrutide Achieves Up to 30.3%

The body's cells become resistant to insulin, or the pancreas does not produce enough of it, or both - while glucagon continues to drive blood sugar higher

Why GLP-1s May Not Be the Answer for Most Women Over 40 These drugs don't address the root causes of weight gain in midlife women: Hormonal shifts (like declining estrogen) Increased stress and cortisol Changes in sleep, energy, and metabolism Gut microbiome imbalances (which in fact, we know these injections can worsen) Most people regain weight after stopping injections unless they've made sustainable changes alongside the medication

51 These results suggest that GLP1 and GLP1RA may exert antiinflammatory and antifibrotic properties in the endometrium affected by obesity, diabetes, and PCOS

The combination of GLP-1, GIP, and glucagon receptor activity creates a complex but effective glucose-lowering effect

Once we understand your unique needs, Duane and Jeannie collaborate with you to develop a customized weight loss plan

Ambery P, Parker VE, Sumvoll M et al (2018) MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomized, controlled, double-blind, ascending dose and phase 2A study